CN114028318B - 一种男性抗菌液及其制备方法和应用 - Google Patents
一种男性抗菌液及其制备方法和应用 Download PDFInfo
- Publication number
- CN114028318B CN114028318B CN202111198853.7A CN202111198853A CN114028318B CN 114028318 B CN114028318 B CN 114028318B CN 202111198853 A CN202111198853 A CN 202111198853A CN 114028318 B CN114028318 B CN 114028318B
- Authority
- CN
- China
- Prior art keywords
- parts
- male
- solution
- preparation
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 52
- 239000007788 liquid Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 36
- 239000000243 solution Substances 0.000 claims description 36
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical group [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 33
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 claims description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000008367 deionised water Substances 0.000 claims description 27
- 229910021641 deionized water Inorganic materials 0.000 claims description 27
- 230000001105 regulatory effect Effects 0.000 claims description 26
- 230000001737 promoting effect Effects 0.000 claims description 25
- 230000037384 skin absorption Effects 0.000 claims description 25
- 231100000274 skin absorption Toxicity 0.000 claims description 25
- 239000002244 precipitate Substances 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 23
- 230000001954 sterilising effect Effects 0.000 claims description 23
- 239000002245 particle Substances 0.000 claims description 21
- 230000024883 vasodilation Effects 0.000 claims description 20
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 claims description 17
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 claims description 17
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 claims description 17
- 235000011201 Ginkgo Nutrition 0.000 claims description 16
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 16
- 240000000759 Lepidium meyenii Species 0.000 claims description 16
- 235000000421 Lepidium meyenii Nutrition 0.000 claims description 16
- 244000246386 Mentha pulegium Species 0.000 claims description 16
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 16
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 16
- 240000004371 Panax ginseng Species 0.000 claims description 16
- 235000002789 Panax ginseng Nutrition 0.000 claims description 16
- 235000008434 ginseng Nutrition 0.000 claims description 16
- 235000001050 hortel pimenta Nutrition 0.000 claims description 16
- 235000012902 lepidium meyenii Nutrition 0.000 claims description 16
- 239000004475 Arginine Substances 0.000 claims description 15
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 239000000341 volatile oil Substances 0.000 claims description 15
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 14
- 239000004359 castor oil Substances 0.000 claims description 14
- 235000019438 castor oil Nutrition 0.000 claims description 14
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 14
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 13
- 238000004659 sterilization and disinfection Methods 0.000 claims description 11
- 238000005406 washing Methods 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 230000003647 oxidation Effects 0.000 claims description 10
- 238000007254 oxidation reaction Methods 0.000 claims description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 239000006185 dispersion Substances 0.000 claims description 7
- 229910002804 graphite Inorganic materials 0.000 claims description 7
- 239000010439 graphite Substances 0.000 claims description 7
- 238000005119 centrifugation Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- UMPKMCDVBZFQOK-UHFFFAOYSA-N potassium;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[K+].[Fe+3] UMPKMCDVBZFQOK-UHFFFAOYSA-N 0.000 claims description 6
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 230000000304 vasodilatating effect Effects 0.000 claims description 6
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000004317 sodium nitrate Substances 0.000 claims description 4
- 235000010344 sodium nitrate Nutrition 0.000 claims description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 3
- 244000194101 Ginkgo biloba Species 0.000 claims description 3
- 239000000908 ammonium hydroxide Substances 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 239000001508 potassium citrate Substances 0.000 claims description 3
- 229960002635 potassium citrate Drugs 0.000 claims description 3
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 3
- 235000011082 potassium citrates Nutrition 0.000 claims description 3
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 3
- 230000000845 anti-microbial effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 235000010333 potassium nitrate Nutrition 0.000 claims description 2
- 239000004323 potassium nitrate Substances 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 229940124532 absorption promoter Drugs 0.000 claims 1
- 206010057672 Male sexual dysfunction Diseases 0.000 abstract description 16
- 244000052616 bacterial pathogen Species 0.000 abstract description 12
- 208000015181 infectious disease Diseases 0.000 abstract description 7
- 230000001568 sexual effect Effects 0.000 abstract description 7
- 230000035946 sexual desire Effects 0.000 description 37
- 230000000694 effects Effects 0.000 description 25
- 241000218628 Ginkgo Species 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 13
- 235000011187 glycerol Nutrition 0.000 description 13
- 230000002708 enhancing effect Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000035807 sensation Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 208000010228 Erectile Dysfunction Diseases 0.000 description 7
- 201000001881 impotence Diseases 0.000 description 7
- 210000003899 penis Anatomy 0.000 description 6
- 238000001223 reverse osmosis Methods 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 5
- 239000003163 gonadal steroid hormone Substances 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 201000001880 Sexual dysfunction Diseases 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000916 dilatatory effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000004392 genitalia Anatomy 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 231100000872 sexual dysfunction Toxicity 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000001856 erectile effect Effects 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 230000008338 local blood flow Effects 0.000 description 3
- 230000018052 penile erection Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 206010024419 Libido decreased Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 230000005582 sexual transmission Effects 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 241000893536 Epimedium Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000005226 corpus cavernosum Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229930184727 ginkgolide Natural products 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种男性抗菌液及其制备方法,首先制备好纳米银抗菌颗粒,再将其杀菌成分与去离子水、血管扩张成分、性欲调节成分、皮肤促吸收剂、增溶剂共混制得男性抗菌液。该抗菌液主要应用于男性抗菌领域,一方面可以防止病原菌经性传播,保证健康的性生活;另一方面,可以对病原菌感染引起的男性性功能障碍起到治疗作用。
Description
技术领域
本发明涉及卫生用品领域,特别涉及一种抗菌液及其制备方法和应用。
背景技术
由于环境污染、工作和生活压力、不良的生活习惯等诸多方面的影响,不少男士的健康出现问题,发生性功能障碍例如勃起功能障碍和早泄等亚健康状况。不仅导致患者 身体健康,还影响生活质量。
近年来,男性性功能障碍的患病人数逐年增加,严重影响患者身心健康。临床上治疗勃起障碍的方法主要包括口服药物西地那非,这种药物在疗效较好,但有全身性副作用高、价格昂贵、起效慢等缺点;另一种治疗方法是给病人阴茎海绵体注射血管扩张剂如酚妥拉明、前列腺素E1等,这种治疗方法会给使用者造成疼痛、创伤,还可能造成感染、海绵体病变等炎症后果。外用给药具有作用部位精准、副作用小、不会引起全身性副作用等优点,是治疗男性勃起障碍、改善男性性功能的重要治疗方式。但是,目前临床上缺乏用于治疗男性勃起障碍的外用产品。因此,开发一款安全、高效的男性外用促阴茎勃起产品具有重要意义。
精氨酸、原儿茶素均有舒张血管、增加局部血流量,改善勃起障碍的作用。根据传统中医药理论,银杏和薄荷具有活血的功效,现代药理学研究也表明了银杏提取物和薄 荷精油具有舒张血管、增加局部血流量,改善勃起功能障碍。
随着年纪的增大、工作和生活压力的影响等因素,导致男性阴虚肾亏,男性雄性激素和性激素等分泌物减少,性欲降低,导致生活受到影响。通过滋阴补肾,调节男性激 素分泌,可以有效提升性欲望。玛咖、高丽参具有滋阴补肾的功效,具有改善性功能障 碍的作用。淫羊藿苷,可促进男性性激素和雄性激素分泌,提高男性性欲。费洛蒙,又叫做荷尔蒙,能够增强两性性欲。
纳米银具有很强的杀菌作用,并且具有杀菌范围广、无副作用、无刺激性等特点,在临床上具有很好的使用效果。在男性性功能产品中添加纳米银杀菌成分,对男性生殖 器起到杀菌作用,一方面可以防止病原菌经性传播,保证健康的性生活;另一方面,可 以对病原菌感染引起的男性性功能障碍起到治疗作用。现有纳米银男性抗菌液与其他组分进行复配使用已达到较好的杀菌效果,该抗菌液不仅对男性生殖器起到杀菌作用,还 有其他复配组分的疗效,但实际上很多其它组分与纳米银之间的效果会相互抵消,有的 甚至会导致纳米银杀菌效果完全消失。所以急需研发一种稳定存在的具有多重医疗效果 的男性抗菌液。
发明内容
针对现有技术不足,本发明解决的技术问题是,提供一种既能防止病原菌经性传播,保证健康的性生活;又能对病原菌感染引起的男性性功能障碍起到治疗作用的男性 抗菌液。
为解决上述技术问题,本发明采用的技术方案是:
一种男性抗菌液,按质量份数计包括:70~90份去离子水、2~5份血管扩张成分、3~8份性欲调节成分、0.01~0.1份杀菌成分、10~20份皮肤促吸收剂、0.1~1份增溶剂。
更进一步地,所述杀菌成分为纳米银颗粒,具体制备过程如下:
S1纳米银颗粒原料的准备:分别准备溶液A和同载体溶液,具体制备过程如下:
按质量分数计,将0.8-1.5份氧化氮化碳和500-600份纯水充分分散,制得同载体分 散液;
按质量分数计,将4-4.5份硝酸银溶于80-100份纯水中,再加入氢氧化铵调节pH值至7-8,制得溶液A;
S2纳米银颗粒的制备:按质量分数计,将10-15份还原剂和9000-11000份纯水在5-10℃下混合均匀,再依次加入S1所得同载体分散液和S1所得溶液A,充分混合均匀 后制得溶液B,然后将溶液B经离心、静置后得上清液和沉淀物,然后将所述沉淀物用 纯水洗涤;再重复上述离心、静置、洗涤过程直至上清液PH值为中性时停止反应,得 最终沉淀物;最终沉淀物经冷冻干燥后,得纳米银颗粒。
更进一步地,所述S1中氧化氮化碳由以下制备方法制备而成:
步骤一:按质量分数计,向反应容器中投入4×104-9×104份混酸液,并冷却至10℃以下;再分别加入1×103-1.5×103份石墨相氮化碳和0.5×103-1.5×103份氧化促进剂,并充分搅拌使其分散均匀;最后加入1-5份氧化稳定剂,并充分搅拌使其分散均匀,得溶 液E;
步骤二:保持10℃以下,并按质量分数计,向步骤一所得溶液E中加入3×103-5×103份高铁酸钾,并充分搅拌1.5-2h;再升温至25-35℃,加入2×103-4×103份高铁酸钾,并充分搅拌2-3h;最后升温至45-50℃搅拌1.5-2h,得溶液F;
步骤三:将步骤二所得溶液F经离心、静置后得上清液和沉淀物,然后将所述沉淀物用纯水洗涤;再重复上述离心、静置、洗涤过程直至上清液PH值为6.5-7.5时停止,得最终沉淀物;
步骤四:将步骤三所得最终沉淀物经真空冷冻干燥机冷冻干燥后,得氧化石墨相氮 化碳;
步骤一中,所述混酸液为硫酸和盐酸的混合溶液,其中,硫酸与盐酸质量比为 30:1-70:1;
步骤一中,所述氧化稳定剂为高碘酸和柠檬酸的混合物,其中高碘酸和柠檬酸的质 量比为1:2-2:1;
步骤一中,所述氧化促进剂为硝酸钠、硝酸钾中至少一种。
更进一步地,特征在于,S2中,所述还原剂为柠檬酸钾、柠檬酸钠中至少一种。
5、根据权利要求1所述的抗菌液,其特征在于,所述血管扩张成分按质量份数计包括0.2-2份精氨酸、0.1-1份原儿茶素、0.1-1份银杏提取物、0.1-1份薄荷精油。
更进一步地,所述性欲调节成分按质量份数计包括1-4份玛咖提取物、1-2份高丽参提取物、0.5-1份费洛蒙、0.5-2份淫羊藿苷。
更进一步地,所述皮肤促吸收剂为甘油、二甲亚砜、水溶性氮酮中的至少一种。皮肤促吸收剂优选为按质量份数计5-10份甘油、0.1-0.5份二甲亚砜、1-3份水溶性氮酮的 混合物。
更进一步地,所述的增溶剂为PEG-40氢化蓖麻油。
基于同一发明构思,本申请还提供了上述抗菌液的制备方法,包括如下步骤:
第一步:将制备所需的所有仪器、机械设备进行清洗、消毒备用;
第二步:将权利要求1-8任一项所述的配方充分混合,得男性抗菌液;
第三步:将第二步所得男性抗菌液负压灌装。
基于同一发明构思,本申请还提供了上述和上述的制备方法制备的男性抗菌液的应 用,所述男性抗菌液主要用于男性抗菌。一方面可以防止病原菌经性传播,保证健康的性生活;另一方面,可以对病原菌感染引起的男性性功能障碍起到治疗作用。
本发明一种改善男性性功能障碍,增强性欲的外用男性抗菌液及其制备防范,包括去离子水、血管扩张成分、性欲调节成分、杀菌成分、皮肤促吸收成分、增溶剂。本 发明不含激素及刺激性化学成分,使用安全,无副作用。其中性欲调节成分包括玛咖提 取物、高丽参提取物、费洛蒙、淫羊藿苷,可以通过诱导男性雄性激素、性激素、前列腺素等物质的分泌,增强性欲,改善性欲低下。淫羊藿苷,中药淫羊藿的主要药效成分, 具有补肾壮阳的作用;现代药理学研究表明,淫羊藿苷能促进精液分泌,刺激感觉神经, 引起性兴奋;此外,淫羊藿苷还能促进性腺功能,提高性激素水平。费洛蒙可以通过刺 激垂体,促进促性腺激素的分泌。玛咖提取物和高丽参提取物,均有滋阴补肾,提高性欲望的作用。
本发明,血管扩张剂包括精氨酸、原儿茶素、银杏提取物、薄荷精油。精氨酸、 原儿茶素具有扩张血管、增加阴茎供血,促进勃起,改善性功能障碍。传统的中医药理 论认为,银杏和薄荷具有活血的作用;现代药理学研究表明,银杏中的主要成分银杏总 黄酮、银杏内酯具有扩张血管、保护血管内皮组织、增加阴茎供血的作用;薄荷精油中薄荷醇等有效成分增加局部供血、发热的功效。
本发明中加入杀菌成分纳米银,可对细菌、真菌、衣原体、病毒等病原体起到杀 灭作用。根据第三方权威机构的检测,本发明可以对大肠杆菌、金黄色葡萄球菌、白色 念珠菌、HPV病毒起到卓越的杀灭效果。通过加入纳米银杀菌剂,可以防止病原菌经性传播,保证健康的性生活,并且可以对病原菌感染引起的男性性功能障碍起到治疗作用。
甘油、二甲亚砜、水溶性氮酮具有增强药物溶解度,良好的促透皮作用。因此, 一种改善男性性功能障碍,增强性欲的外用男性抗菌液中加入皮肤促吸收物质,能够起 到增强药物疗效,缩短起效时间的作用。
与现有技术相比,本发明的有益效果为:本发明具有改善男性性功能障碍,增强性欲的作用。与现有的技术相比,本发明使用了更加合理的配制,通过血管扩张成分和性欲调节成分间合理、精确的配伍,有效改善男性勃起障碍和性欲低下。血管扩张成分可以促使男性私密部位局部血液循环、发热的功效,立即刺激产生短期性欲;性欲调节成分加入可以提高性激素水平、延长勃起时间。
本发明加入皮肤促吸收剂,有助于血管扩张成分和性欲调节成分透过角质层和表皮, 得以在皮肤中更深入地缓释,促进血管扩张成分和性欲调节成分的吸收,克服了利用度 低、起效慢等缺点,延长在体内发挥作用。
与现有的技术相比,本发明通过加入纳米银,起到生殖器杀菌消毒的作用,可以防止病原菌经性传播,也可以对病原菌感染引起的男性性功能障碍起到治疗作用。
具体实施方式
氧化氮化碳的制备:
步骤一:先将60g 98%的浓硫酸、2g浓盐酸混合然后倒入反应瓶中,反应瓶放入冰水浴中冷却至6℃。再将1g石墨相氮化碳和1g硝酸钠加入反应瓶中,并充分搅拌25 分钟使其分散均匀;最后加入0.001g高碘酸、0.002g柠檬酸搅拌10min得溶液E。
步骤二:保持冰水浴10℃,溶液E中缓慢加入4g高铁酸钾,避免产生气泡。继续搅拌2h。继续分次加入3g高铁酸钾,保持30℃搅拌2h。升温至45℃搅拌2h,得溶液F。
步骤三:溶液F转速10000rpm离心60min。静置分层20min,静置后得上清液和沉淀物, 将上清液倒出。沉淀物加入50g纯水洗涤,重复上述离心、静置、洗涤过程直至上清液PH值为7.0,得最终沉淀物2.95g。
步骤四:将步骤三所得最终沉淀物经真空冷冻干燥机冷冻干燥后,得氧化石墨相氮化碳 0.78g。
杀菌成分(纳米银颗粒)的制备:
S1纳米银颗粒原料的准备:分别准备溶液A和同载体溶液,具体制备过程如下:
按质量分数计,将1.0g氧化氮化碳(源自上述制备过程制得的氧化氮化碳)和550g纯水,经搅拌15min,然后使用超声波分散机分散40min,充分分散后,制得同载体分散液;
按质量分数计,将4g硝酸银溶于80g纯水中,再加入氢氧化铵调节pH值至7,制 得溶液A;
S2纳米银颗粒的制备:
按质量分数计,将15g柠檬酸钾和11000g纯水在5℃冰水浴下混合均匀,再依次 加入S1所得同载体分散液和S1所得溶液A,依次经搅拌20min和超声30min充分混 合均匀后,得制得溶液B,然后将溶液B经转速6000rpm离心30分钟、静置30min后 得上清液和沉淀物,然后将所述沉淀物用纯水洗涤;再重复上述离心、静置、洗涤过程 直至上清液PH值为中性时停止反应,得最终沉淀物;最终沉淀物经冷冻干燥后,得纳 米银颗粒;
下述实施例和对比例所用的杀菌成分均由上述制备方法制备而成。下述实施例和对比 例中所用的原料,如无特殊说明,均为市售购买产品。玛咖提取物、高丽参提取物产品规格是10:1水溶型。
实施例1
本具体实施方式采用以下技术方案:一种改善男性性功能障碍,增强性欲的外用男 性抗菌液及其制备防范,包括去离子水、血管扩张成分、性欲调节成分、杀菌成分、皮 肤促吸收成分、增溶剂。
其中,血管扩张成分为精氨酸、原儿茶素、银杏提取物、薄荷精油;性欲调节成分为玛咖提取物、高丽参提取物、淫羊藿苷、费洛蒙;杀菌成分为纳米银颗粒;皮肤促吸 收成分为甘油、二甲亚砜、水溶性氮酮;增溶剂为PEG-40氢化蓖麻油。
其中,所述的去离子水有RO反渗透的方法制得,是去离子水的制取更加方便。
其中,按质量份数计,所述的去离子水76.86份,所述的血管扩张成分精氨酸2份、原儿茶素0.5份、银杏提取物1份,薄荷精油0.5份;性欲调节成分玛咖提取物3份, 高丽参提取物1.5份,淫羊藿苷1份,费洛蒙1份;杀菌成分纳米银颗粒0.04份;皮肤 促吸收成分甘油10份,水溶性氮酮2份;二甲亚砜0.1份;增溶剂PEG-40氢化蓖麻油 0.5份。
实施例2
本具体实施方式采用以下技术方案:一种改善男性性功能障碍,增强性欲的外用男 性抗菌液及其制备防范,包括去离子水、血管扩张成分、性欲调节成分、杀菌成分、皮 肤促吸收成分、增溶剂。
其中,血管扩张成分为精氨酸、原儿茶素、银杏提取物、薄荷精油;性欲调节成分为玛咖提取物、高丽参提取物、淫羊藿苷、费洛蒙;杀菌成分为纳米银颗粒;皮肤促吸 收成分为甘油、二甲亚砜、水溶性氮酮;增溶剂为PEG-40氢化蓖麻油。
其中,所述的去离子水有RO反渗透的方法制得,是去离子水的制取更加方便。
其中,按质量份数计,所述的去离子水77.488份,所述的血管扩张成分精氨酸1份、原儿茶素1份、银杏提取物0.5份,薄荷精油0.2份;性欲调节成分玛咖提取物2 份,高丽参提取物1.5份,淫羊藿苷1份,费洛蒙占0.8份;杀菌成分纳米银颗粒0.012 份;皮肤促吸收成分甘油13份,水溶性氮酮1份;二甲亚砜0.2份;增溶剂PEG-40氢 化蓖麻油0.3份。
实施例3
本具体实施方式采用以下技术方案:一种改善男性性功能障碍,增强性欲的外用男 性抗菌液及其制备防范,包括去离子水、血管扩张成分、性欲调节成分、杀菌成分、皮 肤促吸收成分、增溶剂。
其中,血管扩张成分为精氨酸、原儿茶素、银杏提取物、薄荷精油;性欲调节成分为玛咖提取物、高丽参提取物、淫羊藿苷、费洛蒙;杀菌成分为纳米银颗粒;皮肤促吸 收成分为甘油、二甲亚砜、水溶性氮酮;增溶剂为PEG-40氢化蓖麻油。
其中,所述的去离子水有RO反渗透的方法制得,是去离子水的制取更加方便。
其中,所述的去离子水73.48份,所述的血管扩张成分精氨酸1.5份、原儿茶素0.8份、银杏提取物1.5份,薄荷精油0.2份;性欲调节成分玛咖提取物占总混合物的4份, 高丽参提取物1份,淫羊藿苷0.8份,费洛蒙占0.6份;杀菌成分纳米银颗粒0.02份; 皮肤促吸收成分甘油14份,水溶性氮酮1份;二甲亚砜0.1份;增溶剂PEG-40氢化蓖 麻油1份。
对比例1
本具体实施方式采用以下技术方案:一种改善男性性功能障碍,增强性欲的外用男 性抗菌液及其制备防范,包括去离子水、血管扩张成分、杀菌成分、皮肤促吸收成分、 增溶剂。没有性欲调节成分。
其中,血管扩张成分为精氨酸、原儿茶素、银杏提取物、薄荷精油;杀菌成分为纳米银颗粒;皮肤促吸收成分为甘油、二甲亚砜、水溶性氮酮;增溶剂为PEG-40氢化蓖 麻油。
其中,所述的去离子水有RO反渗透的方法制得,是去离子水的制取更加方便。
其中,所述的去离子水83.06份,所述的血管扩张成分精氨酸2份、原儿茶素0.5份、银杏提取物1份,薄荷精油0.5份;杀菌成分纳米银0.04份;皮肤促吸收成分甘油 10份,水溶性氮酮占混合物总重量的2份;二甲亚砜0.4份;增溶剂PEG-40氢化蓖麻 油0.5份。
对比例2
本具体实施方式采用以下技术方案:一种改善男性性功能障碍,增强性欲的外用男 性抗菌液及其制备防范,包括去离子水、性欲调节成分、杀菌成分、皮肤促吸收成分、 增溶剂。没有血管扩张成分。
其中,性欲调节成分为玛咖提取物、高丽参提取物、淫羊藿苷、费洛蒙;杀菌成分为纳米银颗粒;皮肤促吸收成分为甘油、二甲亚砜、水溶性氮酮;增溶剂为PEG-40氢 化蓖麻油。
其中,所述的去离子水有RO反渗透的方法制得,是去离子水的制取更加方便。
其中,所述的去离子水80.46份,所述的性欲调节成分玛咖提取物3份,高丽参提取物1.5份,淫羊藿苷1份,费洛蒙占1份;杀菌成分纳米银0.04份;皮肤促吸收成分 甘油10份,水溶性氮酮占混合物总重量的2份;二甲亚砜0.5份;增溶剂PEG-40氢化 蓖麻油0.5份。
对比例3
本具体实施方式采用以下技术方案:一种改善男性性功能障碍,增强性欲的外用男 性抗菌液及其制备防范,包括去离子水、血管扩张成分、性欲调节成分、杀菌成分、增 溶剂。没有皮肤促吸收成分。
其中,血管扩张成分为精氨酸、原儿茶素、银杏提取物、薄荷精油;性欲调节成分为玛咖提取物、高丽参提取物、淫羊藿苷、费洛蒙;杀菌成分为纳米银颗粒;增溶剂为 PEG-40氢化蓖麻油。
其中,所述的去离子水有RO反渗透的方法制得,是去离子水的制取更加方便。
其中,所述的去离子水88.96份,所述的血管扩张成分精氨酸2份、原儿茶素0.5份、银杏提取物1份,薄荷精油0.5份;性欲调节成分玛咖提取物3份,高丽参提取物 1.5份,淫羊藿苷1份,费洛蒙占1份;杀菌成分纳米银0.04份;增溶剂PEG-40氢化 蓖麻油0.5份。
实施例1与对比例1、2、3效果比较
招募本单位男性受试者10名,年龄35-45岁。取5~10ml男性抗菌液,采用涂抹的方式,均匀的涂抹生殖器。参照以下打分标准进行药效的打分:
表1热感打分标准
热感 | 无明显感觉 | 轻微热感 | 温和热感 | 强烈热感 | 刺痛感 |
分值 | 0 | 3 | 4 | 2 | 1 |
注:热感是指涂抹给药后,阴茎的粗触觉感受
表2发热时间打分标准
注:发热时间是指涂抹给药后,至阴茎有热感所需的时间
表3性欲打分标准
性欲 | 无兴奋感 | 轻微兴奋感 | 明显兴奋感 |
打分 | 0 | 2 | 4 |
注:此处打分要求是根据:给药后,30分钟内是否会引起性兴奋感。
表4勃起时间打分标准
勃起时间 | 1~5分钟 | 5~10分钟 | 10~20分钟 | 20分钟以上 | 无 |
打分 | 8 | 5 | 3 | 2 | 0 |
注:勃起时间是指涂抹给药后,至阴茎勃起所需的时间
根据以上标准,对产品效果进行打分,其结果如下:
表5实施例1与对比例1、2、3效果比较
实施例1 | 对比例1 | 对比例2 | 对比例3 | |
热感 | 4 | 4 | 0 | 3 |
发热时间 | 4 | 4 | 0 | 2 |
性欲 | 4 | 2 | 0 | 4 |
勃起时间 | 8 | 5 | 0 | 3 |
实施例1和对比例1比较,实施例1产品中添加了性欲调节成分,能增强性欲,促 进阴茎勃起。对比例2和实施例1比较,产品中少了血管扩张成分,对阴茎勃起功能的 调节无作用,表明血管扩张成分对性功能障碍的治疗起着至关重要的作用。对比例3与 实施例1比较,产品中缺少了皮肤促吸收成分,给药后,阴茎有轻微热感,发热时间延 长,勃起时间也延长,表明皮肤促吸收成分能够增加药物的吸收,缩短产品起效时间。
第三方检测机构英格尔检测多次整体皮肤刺激试验
一材料和动物
1样品:男性抗菌液
2动物:新西兰兔,由湖南太平生物科技有限公司提供。
3环境:温度22-25℃,相对湿度54份-58份
二方法
检测依据:消毒技术规范(2002版)2.3.3.3.3
三结果
全部受试动物涂药区皮肤在染毒后14d观察期内均未见红斑、水肿及其他异常;受试动物对照区皮肤在观察期内无异常现象。每天每只动物刺激反应的平均积分(刺激指数)为0.
男性抗菌液重金属含量
该样品的铅含量未检出(小于0.09mg/kg),汞含量未检出(小于0.0033mg/kg), 砷含量汞含量未检出(小于0.0033mg/kg)。
Claims (4)
1.一种男性抗菌液,其特征在于,按质量份数计,由以下组分组成:70~90份去离子水、2~5份血管扩张成分、3~8份性欲调节成分、0.01~0.1份杀菌成分、10~20份皮肤促吸收剂、0.1~1份增溶剂;
所述杀菌成分为纳米银颗粒,具体制备过程如下:
S1纳米银颗粒原料的准备:分别准备溶液A和同载体溶液,具体制备过程如下:
按质量分数计,将0.8-1.5份氧化氮化碳和500-600份纯水充分分散,制得同载体分散液;
按质量分数计,将4-4.5份硝酸银溶于80 -100份纯水中,再加入氢氧化铵调节pH值至7-8,制得溶液A;
S2纳米银颗粒的制备:按质量分数计,将10-15份还原剂和9000-11000份纯水在5-10℃下混合均匀,再依次加入S1所得同载体分散液和S1所得溶液A,充分混合均匀后制得溶液B,然后将溶液B经离心、静置后得上清液和沉淀物,然后将所述沉淀物用纯水洗涤;再重复上述离心、静置、洗涤过程直至上清液PH值为中性时停止反应,得最终沉淀物;最终沉淀物经冷冻干燥后,得纳米银颗粒;
所述S1中氧化氮化碳由以下制备方法制备而成:
步骤一:按质量分数计,向反应容器中投入4×104-9×104份混酸液,并冷却至10℃以下;再分别加入1×103-1.5×103份石墨相氮化碳和0.5×103-1.5×103份氧化促进剂,并充分搅拌使其分散均匀;最后加入1-5份氧化稳定剂,并充分搅拌使其分散均匀,得溶液E;
步骤二:保持10℃以下,并按质量分数计,向步骤一所得溶液E中加入3×103-5×103份高铁酸钾,并充分搅拌1.5-2h;再升温至25-35℃,加入2×103-4×103份高铁酸钾,并充分搅拌2-3h;最后升温至45-50℃搅拌1.5-2h,得溶液F;
步骤三:将步骤二所得溶液F经离心、静置后得上清液和沉淀物,然后将所述沉淀物用纯水洗涤;再重复上述离心、静置、洗涤过程直至上清液PH值为6.5-7.5时停止,得最终沉淀物;
步骤四:将步骤三所得最终沉淀物经真空冷冻干燥机冷冻干燥后,得氧化石墨相氮化碳;
步骤一中,所述混酸液为硫酸和盐酸的混合溶液,其中,硫酸与盐酸质量比为30:1-70:1;
步骤一中,所述氧化稳定剂为高碘酸和柠檬酸的混合物,其中高碘酸和柠檬酸的质量比为1:2-2:1;
步骤一中,所述氧化促进剂为硝酸钠、硝酸钾中至少一种;
S2中,所述还原剂为柠檬酸钾、柠檬酸钠中至少一种;
所述皮肤促吸收剂为甘油、二甲亚砜、水溶性氮酮中的至少一种;
所述血管扩张成分按质量份数计,由以下组分组成:0.2-2份精氨酸、0.1-1份原儿茶素、0.1-1份银杏提取物、0.1-1份薄荷精油;
所述性欲调节成分按质量份数计,由以下组分组成:1-4份玛咖提取物、1-2份高丽参提取物、0.5-1份费洛蒙、0.5-2份淫羊藿苷。
2.根据权利要求1所述的男性抗菌液,其特征在于,所述的增溶剂为PEG-40氢化蓖麻油。
3.如权利要求1或2所述的男性抗菌液的制备方法,其特征在于,包括如下步骤:
第一步:将制备所需的所有仪器、机械设备进行清洗、消毒备用;
第二步:将权利要求1或2所述的配方充分混合,得男性抗菌液;
第三步:将第二步所得男性抗菌液负压灌装。
4.根据权利要求1或2所述的男性抗菌液和权利要求3所述的制备方法制备的男性抗菌液,其特征在于,所述男性抗菌液主要用于男性抗菌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111198853.7A CN114028318B (zh) | 2021-10-14 | 2021-10-14 | 一种男性抗菌液及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111198853.7A CN114028318B (zh) | 2021-10-14 | 2021-10-14 | 一种男性抗菌液及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114028318A CN114028318A (zh) | 2022-02-11 |
CN114028318B true CN114028318B (zh) | 2023-11-21 |
Family
ID=80134925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111198853.7A Active CN114028318B (zh) | 2021-10-14 | 2021-10-14 | 一种男性抗菌液及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114028318B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1328827A (zh) * | 2001-04-20 | 2002-01-02 | 朱红军 | 纳米银前列腺炎抗菌消炎凝胶及其工业化生产工艺 |
CN101559219A (zh) * | 2009-04-17 | 2009-10-21 | 王和广 | 一种用于包茎和男科炎症及性功能障碍的制剂及其生产方法 |
CN104672159A (zh) * | 2015-01-21 | 2015-06-03 | 扬州大学 | 一种氧化石墨相氮化碳及其制备方法与应用 |
CN109316528A (zh) * | 2018-11-13 | 2019-02-12 | 宁岱 | 一种治疗男性勃起功能障碍的药物及其制备方法 |
-
2021
- 2021-10-14 CN CN202111198853.7A patent/CN114028318B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1328827A (zh) * | 2001-04-20 | 2002-01-02 | 朱红军 | 纳米银前列腺炎抗菌消炎凝胶及其工业化生产工艺 |
CN101559219A (zh) * | 2009-04-17 | 2009-10-21 | 王和广 | 一种用于包茎和男科炎症及性功能障碍的制剂及其生产方法 |
CN104672159A (zh) * | 2015-01-21 | 2015-06-03 | 扬州大学 | 一种氧化石墨相氮化碳及其制备方法与应用 |
CN109316528A (zh) * | 2018-11-13 | 2019-02-12 | 宁岱 | 一种治疗男性勃起功能障碍的药物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
Environmentally Sustainable Fabrication of Ag@g-C3N4 Nanostructures and Their Multifunctional Efficacy as Antibacterial Agents and Photocatalysts;Mohammad Ehtisham Khan 等,;《ACS Applied Nano Materials》;第1卷;第2913-2914 页 * |
Also Published As
Publication number | Publication date |
---|---|
CN114028318A (zh) | 2022-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI119498B (fi) | Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä | |
JP5118633B2 (ja) | 医療用デバイスおよび医薬製剤において有用な粘膜付着性キシログルカン含有製剤 | |
US5891915A (en) | Method for enhancing female sexual response and an ointment therefor | |
CN109078165A (zh) | 一种用于女性私处护理的组合物及其制备方法与应用 | |
CN106466454A (zh) | 一种预防及治疗妇科炎症的凝胶剂 | |
CN106109451A (zh) | 一种抗菌制剂及其制备方法 | |
CN108992451A (zh) | 一种具有消炎止痒抗菌功效的乳膏及其制备方法 | |
WO1999038472A2 (en) | Topical vasodilatory gel composition and methods of use and production | |
CN103239428B (zh) | 避孕贴及其制备方法 | |
CN106619780A (zh) | 一种妇科抗菌凝胶 | |
CN110051773A (zh) | 一种含有金花茶具有抗菌修复腔道炎症的凝胶及其制法 | |
CN114028318B (zh) | 一种男性抗菌液及其制备方法和应用 | |
CN108553499A (zh) | 一种天然有效成分的妇科抑菌避孕凝胶及其制备方法 | |
CN109010685A (zh) | 一种妇科用抑菌泡沫气雾剂及其制备方法 | |
CZ283011B6 (cs) | Farmaceutická kompozice pro léčení příznaků vulvitidy nebo vulvovaginitidy a způsob její přípravy | |
CN108938703A (zh) | 快速抗菌的妇科凝胶 | |
CN112022902A (zh) | 一种碳点改性氟康唑桉叶油微乳凝胶制备方法及应用 | |
US20100112102A1 (en) | Therapeutic compositions for the treatment of benigh prostate hyperplasia, prostatitis, impotence, infertility and prostate cancer and a method for the use thereof | |
CN106177274A (zh) | 一种避孕凝胶组合物及其制备方法 | |
CN112076215A (zh) | 一种改善生殖道微生态的抗菌组合物及其应用 | |
CN110623919A (zh) | 一种妇科用富含氢离子酸性养护避孕凝胶及其制备方法 | |
CN104941010B (zh) | 一种医用阴道润滑液及其制备方法 | |
CN1491647A (zh) | 经皮式用于治疗阳痿和女性性冷淡并防治性病的组合物 | |
US20050214243A1 (en) | Feminine homeopathic formulations | |
RU2765823C1 (ru) | Способ использования увлажняющего геля для интимной гигиены |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |